Evidio Domingo-Musibay

13PUBLICATIONS
70CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersMolecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Solid tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (13)

|Jun 02, 2025
Long-Term Efficacy and Safety of Lifileucel Tumor-Infiltrating Lymphocyte Cell Therapy in Patients With Advanced Melanoma: A 5-Year Analysis of the C-144-01 Study.

Theresa Medina, Jason A Chesney, Harriet M Kluger

|Apr 15, 2025
Neoadjuvant cobimetinib and atezolizumab with or without vemurafenib for stage III melanoma: outcomes and the impact of the microbiome from the NeoACTIVATE trial.

Matthew S Block, Garth D Nelson, Jun Chen

|Feb 16, 2024
Neoadjuvant cobimetinib and atezolizumab with or without vemurafenib for high-risk operable Stage III melanoma: the Phase II NeoACTIVATE trial.

Tina J Hieken, Garth D Nelson, Thomas J Flotte

|Nov 14, 2023
Multi-omic profiling reveals discrepant immunogenic properties and a unique tumor microenvironment among melanoma brain metastases.

Gino K In, Jennifer R Ribeiro, Jun Yin

|Mar 31, 2023
SALVO: Single-Arm Trial of Ipilimumab and Nivolumab as Adjuvant Therapy for Resected Mucosal Melanoma.

Lisa A Kottschade, Gregory Russell Pond, Anthony J Olszanski

|Jan 05, 2023
Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study.

Jason Chesney, Karl D Lewis, Harriet Kluger

Pageof 3

Frequent Collaborators

3 joint publications

Robert R McWilliams

3 joint publications

Matthew Stephen Block

3 joint publications

Eric Whitman

3 joint publications

Amod Sarnaik